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Based on data collected by the European Antimicrobial 
Resistance Surveillance Network (EARS-Net) and the 
former EARSS, the present study describes the trends 
in antimicrobial susceptibility patterns and occur-
rence of invasive infections caused by Escherichia coli 
and Staphylococcus aureus in the period from 2002 
to 2009. Antimicrobial susceptibility results from 
198 laboratories in 22 European countries reporting 
continuously on these two microorganisms during 
the entire study period were included in the analy-
sis. The number of bloodstream infections caused by 
E. coli increased remarkably by 71% during the study 
period, while bloodstream infections caused by 
S. aureus increased by 34%. At the same time, an 
alarming increase of antimicrobial resistance in E. coli 
was observed, whereas for S. aureus the proportion of 
meticillin resistant isolates decreased. The observed 
trend suggests an increasing burden of disease caused 
by E. coli. The reduction in the proportion of meticillin-
resistant S. aureus and the lesser increase in S. aureus 
infections, compared with E. coli, may reflect the suc-
cess of infection control measures at hospital level in 
several European countries.
Introduction
Escherichia coli and	Staphylococcus aureus	are	the	main	
causes	of	bloodstream	infections	(BSIs)	in	humans.	The	
antimicrobial	resistance	of	E. coli	causing	BSI	is	increas-
ing	alarmingly	across	Europe,	while	meticillin-resistant	
S. aureus	(MRSA)	is	decreasing	in	several	countries	[1].	
The	 antimicrobial	 susceptibility	 of	 these	 microorgan-
isms	 and	 other	 selected	 bacterial	 pathogens	 causing	
invasive	 infections	 has	 been	 monitored	 for	 a	 decade	
by	the	European	Antimicrobial	Resistance	Surveillance	
System	 (EARSS)	 [1].	 Coordination	 and	 administra-
tion	 of	 the	 EARSS	 project,	 previously	 conducted	 by	
the	 Dutch	 National	 Institute	 of	 Public	 Health	 and	 the	
Environment	 (RIVM),	 was	 transferred	 to	 the	 European	
Centre	for	Disease	Prevention	and	Control	 (ECDC)	on	1	
January	2010,	and	the	network	was	renamed	European	
Antimicrobial	 Resistance	Surveillance	Network	 (EARS-
Net).	The	 first	data	collection	by	EARS-Net	 (antimicro-
bial	 susceptibility	 data	 referring	 to	 2009)	 took	 place	
during	June	and	July	2010.	
Whereas	 detailed	 analysis	 and	 trends	 at	 the	 national	
level	are	available	in	the	EARSS	and	EARS-Net	reports	
[1,2],	 the	 present	 study	 describes	 the	 trends	 in	 sus-
ceptibility	 patterns	 and	 number	 of	 invasive	 infections	
caused	by	E. coli	and	S. aureus	in	Europe	from	2002	to	
2009,	based	on	data	 from	 laboratories	 reporting	con-
tinuously	during	this	period.	
Methods 
Data	 for	 E. coli	 and	 S. aureus	 BSIs	 were	 extracted	
from	the	EARSS/EARS-Net	database	for	a	convenience	
sample	of	 laboratories	 reporting	susceptibility	 results	
continuously	during	 the	period	 from	2002	 to	2009	 for	
aminopenicillin,	 fluoroquinolones,	 third	 generation	
cephalosporins	and	aminoglycosides	 in	E. coli	 and	 for	
oxacillin	in	S. aureus	[3].	Countries	in	which	no	labora-
tory	participated	for	the	entire	period	or	that	had	only	
a	small	data	set	(less	than	20	isolates	per	microorgan-
ism	 per	 year)	 were	 not	 included	 in	 the	 analysis.	 Only	
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the	 first	 isolate	 per	 patient,	 microorganism	 and	 year	
was	 included	 as	 a	 representative	 sample.	 Sampling	
and	processing	of	isolates	was	done	in	agreement	with	
the	 EARSS	 manual	 2005	 [3].	 Resistance	 (R	 category	
of	S,	 I,	R)	was	defined	by	 the	guidelines	 in	use	 in	 the	
reporting	countries.	
The	 number	 of	 BSIs	 caused	 by	 E. coli	 and	 S. aureus	
and	the	proportions	of	third-generation	cephalosporin-
resistant	 E. coli	 and	 of	 MRSA	 were	 recorded	 for	 each	
year	from	2002	to	2009.	To	assess	the	patterns	of	com-
bined	 resistance	of	E. coli,	 the	 following	antimicrobial	
classes	were	analysed:	aminopenicillins	(ampicillin	and	
amoxicillin),	 aminoglycosides	 (gentamicin,	 tobramy-
cin	 and	 amikacin),	 third-generation	 cephalosporins	
(ceftriaxone,	 cefotaxime	 and	 ceftazidime)	 and	 fluoro-
quinolones	 (ciprofloxacin,	 ofloxacin	 and	 levofloxacin).	
Resistance	to	a	class	was	defined	as	resistance	(R	cate-
gory)	to	at	least	one	agent	in	the	class.	The	significance	
of	the	temporal	linear	trends	for	resistance	proportions	
was	evaluated	by	the	Cochran–Armitage	test	for	trend.
Results
A	total	of	198	laboratories	in	22	countries	continuously	
reported	data	from	2002	to	2009.	The	number	of	labo-
ratories	per	country	 ranged	between	one	 (Iceland	and	
Malta)	and	33	(Czech	Republic),	while	the	mean	number	
of	 E. coli	 and	 S. aureus	 isolates	 reported	 yearly	 per	
country	ranged	from	96	to	1,973	and	from	56	to	1,290,	
respectively	(Table).	
Considering	 the	 whole	 group	 of	 selected	 laborato-
ries,	 the	 reported	number	of	E. coli	BSIs	 increased	by	
71%	from	10,688	in	2002	to	18,240	in	2009	(Figure	1);	
most	of	 the	 rise	 (38%	of	 71%)	 in	E. coli	 BSIs	was	due	
to	 isolates	 resistant	 to	 two	 or	 more	 antimicrobials.	
During	the	same	period,	S. aureus	BSIs	showed	a	34%	
increase	 from	7,855	 to	 10,503	 (Figure	 1).	 In	 the	period	
from	 2002	 to	 2009,	 if	 only	 E.coli	 susceptible	 to	 ami-
nopenicillins,	 third-generation	 cephalosporins,	 fluo-
roquinolones	and	aminoglycosides	are	considered,	the	
number	of	BSIs	 increased	by	39%.	Similarly,	 the	BSIs	
caused	by	meticillin-susceptible	S. aureus	 showed	an	
increase	of	37%.
In	the	period	from	2002	to	2009,	the	proportion	among	
all	E. coli	of	E. coli	resistant	to	third-generation	cepha-
losporins	 increased	 significantly	 from	 1.7%	 to	 8%	
(p<0.001)	and	the	proportion	of	MRSA	decreased	from	
21.5%	 to	 19.7%	 (p<0.001)	 (Figure	 2).	 Similar	 trends	 of	
resistance	 proportions	 as	 observed	 for	 aggregated	
data	of	all	198	laboratories	were	also	observed	at	coun-
try	level	in	18	of	22	countries	for	E. coli,	and	in	seven	of	
22	countries	for	S. aureus.
Table 
Mean annual number of Escherichia coli and Staphylococcus aureus isolates per country reported by laboratories (n=198) 
reporting continuously to EARSS/EARS-Net, 2002–09
Country Number of laboratories
Number of Escherichia coli isolates Number of Staphylococcus aureus isolates
Mean per year (2002–09) Mean per year (2002–09)
Austria 10 802 630
Belgium 9 646 343
Bulgaria 7 96 82
Czech Republic 33 1,837 1,290
Estonia 5 142 125
Finland 5 849 381
France 12 1,583 1,018
Germany 2 156 121
Greece 22 829 472
Hungary 14 446 526
Iceland 1 97 56
Ireland 15 1,086 961
Italy 3 237 166
Luxembourg 4 176 80
Malta 1 104 96
Netherlands 4 291 238
Norway 7 975 467
Portugal 8 559 574
Slovenia 9 572 321
Spain 19 1,973 835
Sweden 3 578 331
United Kingdom 5 641 373
EARSS:	European	Antimicrobial	Resistance	Surveillance	System;	EARS-Net:	European	Antimicrobial	Resistance	Surveillance	Network.
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Combined	 resistance	 in	 E. coli	 (defined	 as	 resistance	
to	 two,	 three	 or	 four	 antimicrobial	 classes	 reported	
to	 EARS-Net)	 showed	 a	 significant	 increase	 (p<0.001)	
(Figure	 3)	 whereas	 single	 resistance	 diminished	 from	
37.1%	in	2002	to	35.8%	in	2009	(p<0.001).	The	propor-
tion	of	E. coli	isolates	susceptible	to	all	four	antimicro-
bial	classes	decreased	from	51.4%	in	2002	to	41.7%	in	
2009	(p<0.001).
Discussion
The	 increase	 in	 antimicrobial	 resistance	 in	 E. coli	
between	 2002	 and	 2009	 was	 evident	 both	 in	 the	
observed	 increase	 of	 combined	 resistance	 and	 in	 the	
reduction	 of	 full	 susceptibility	 to	 the	 antimicrobi-
als	 included	 in	 the	 analysis.	 In	 the	 same	 time	 period	
and	 considering	 the	 same	 data	 source,	 a	 significant	
decrease	of	meticillin	resistance	was	observed	for
S. aureus.	 For	 this	 species,	 the	 number	 of	 BSIs	
increased	 less	 (+34%)	 than	 for	 E. coli	 BSI	 (+71%).	
Consistently,	 increasing	 resistance	 in	E. coli	 and	com-
bined	resistance	of	 invasive	and	non-invasive	 isolates	
was	 reported	 by	 several	 European	 countries	 [4-8].	 At	
the	same	 time,	 the	proportion	of	MRSA	showed	a	sig-
nificant	decrease	in	many	European	countries	[1,2].	The	
numbers	of	BSIs	caused	by	MRSA,	as	 reported	by	 the	
mandatory	surveillance	system	 in	England,	decreased	
by	 56%	 between	 2004	 and	 2008	 [9],	 and	 in	 France	 a	
significant	 decrease	 in	 the	 occurrence	 of	 MRSA	 was	
reported	 in	 2008	 [10].	 A	 similar	 reduction	 in	 the	 rate	
of	 healthcare-associated	 invasive	 MRSA	 infections	
was	observed	 in	 the	general	 population	 in	 the	United	
States	[11].
The	sampling	approach	selected	for	this	study	is	likely	
to	eliminate	a	large	part	of	the	possible	temporal	vari-
ation	 in	 the	 size	 of	 the	 catchment	 population	 behind	
the	numbers.	Based	on	the	available	surveillance	data,	
it	 provides	 the	 best	 possible	 evidence	 of	 the	 increas-
ing	burden	of	disease	caused	by	E. coli	 and	S. aureus	
bacteraemia	 in	 the	 European	 Union.	 Nevertheless,	 if	
the	 population	 covered	 by	 the	 participating	 laborato-
ries	 became	 larger	 during	 the	 study	 period,	 this	may	
have	 contributed	 to	 the	 observed	 increase.	 Likewise,	
the	 sample	 approach	 includes	 laboratories	 without	
taking	 into	account	 the	size	of	 the	country,	and	there-
fore	does	not	allow	detailed	analysis	at	national	level.	
The	disparity	in	the	BSI	trends	for	E. coli	and	S. aureus	
could	partly	be	explained	by	ascertainment	bias	 lead-
ing	to	higher	reporting	of	E. coli	 infections.	This	could	
be	 caused	 by	 an	 increase	 of	 empirical	 treatment	 fail-
ures	 triggering	 delayed	 diagnostic	 procedures	 (blood	
culture).	 A	 similar	 upward	 trend	 in	 the	 number	 of	
reported	 cases	 of	 E. coli	 BSIs	 has	 been	 observed	 by	
Figure 2
Proportion of third-generation cephalosporin-resistant 
Escherichia coli and of meticillin-resistant Staphylococcus 
aureus, EARSS/EARS-Net, 2002-09 (22 countries/198 
laboratories)
EARS-Net:	European	Antimicrobial	Resistance	Surveillance	
Network;	EARSS:	European	Antimicrobial	Resistance	Surveillance	
System.
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Figure 1
Annual number of bloodstream infections caused by 
Escherichia coli and Staphylococcus aureus, EARSS/EARS-
Net, 2002-09 (22 countries/198 laboratories)
EARSS:	European	Antimicrobial	Resistance	Surveillance	System;	
EARS-Net:	European	Antimicrobial	Resistance	Surveillance	
Network.
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Figure 3
Combined resistance of Escherichia coli to 
aminopenicillins, third-generation cephalosporins, 
fluoroquinolones and aminoglycosides, EARSS/EARS-Net, 
2002-09 (22 countries/198 laboratories)
EARSS/EARS-Net:	European	Antimicrobial	Resistance	Surveillance	
Network;	EARSS:	European	Antimicrobial	Resistance	Surveillance	
System.
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the	national	voluntary	surveillance	scheme	in	England,	
Wales,	and	Northern	 Ireland	between	2005	and	2009.	
The	increase	(37%)	in	BSIs	caused	by	E. coli	observed	
by		this	surveillance	system	is	larger	than	the	increase	
in	all	BSIs	reported	during	that	time	period	[12].	
Despite	 the	 study	 limitations,	 the	 observed	 trends	
regarding	 resistance	 to	 third-generation	 cepha-
losporins	 and	 combined	 resistance	 in	 E. coli	 deserve	
further	 consideration.	 According	 to	 the	 results,	 it	
appears	 that	 the	 emergence	 and	 spread	 of	 combined	
resistance	during	the	study	period	was	the	main	factor	
that	 influences	 the	 decline	 in	 antimicrobial	 suscepti-
bility	in	E. coli.	From	2002	to	2009,	a	relative	increase	
of	combined	resistance	with	a	concurrent	 reduction	of	
the	proportion	of	single	resistance	was	observed.	The	
resistance	 pattern	 with	 the	 largest	 relative	 growth	 in	
the	period	from	2002	to	2009	was	resistance	to	all	four	
antimicrobial	classes	under	surveillance:	the	frequency	
of	this	pattern	increased	more	than	fivefold	from	0.6%	
to	3.4%.	This	trend	suggests	that	within	the	subpopu-
lation	of	resistant	isolates,	there	was	a	continuous	rel-
ative	growth	of	 combined	 resistance,	possibly	 caused	
by	the	addition	of	resistance	traits	to	strains	that	were	
already	resistant	to	at	least	one	of	the	considered	anti-
microbial	classes.	This	 trend	may	be	explained	by	 the	
spread	of	multidrug-resistant	plasmids	which	also	con-
tain	genes	 for	 the	extended-spectrum	beta-lactamase	
(ESBL)	production	[13-16].	
Resistance	 trends	 were	 monitored	 using	 interpreta-
tions:	 susceptible,	 intermediate	 or	 resistant	 (SIR)	 [3],	
since	 the	 actual	 minimum	 inhibitory	 concentrations	
(MIC)	 were	 not	 systematically	 available	 from	 partici-
pating	 laboratories.	 Reporting	 MICs	 rather	 than	 SIR	
interpretations	 based	 on	 clinical	 breakpoints	 would	
improve	the	dynamic	monitoring	of	subtle,	incremental	
changes	 in	 antimicrobial	 susceptibility.	Moreover,	 the	
interpretation	 using	 SIR	 categories	 reported	 to	 EARS-
Net	 is	based	on	breakpoints	defined	 in	 the	participat-
ing	 countries’	 guidelines	 over	 time.	 Nevertheless,	 for	
the	 combinations	 of	microorganisms	 and	 antimicrobi-
als	 included	 in	 this	study,	 the	variation	 in	 the	propor-
tion	of	resistance	caused	by	using	different	guidelines	
is	very	limited	(unpublished	data).
Conclusion
This	is	a	serious	concern	since,	 if	 the	increasing	trend	
of	antimicrobial	resistance	and	the	spread	of	ESBL	are	
not	 contained,	 the	 use	 of	 carbapenems	 will	 increase	
favouring	 the	 emergence	 of	 carbapenemase	 produc-
ing	enterobacteria.	This	has	been	already	observed	for	
Klebsiealla pneumoniae	 in	 Greece,	 Israel	 and	 Cyprus	
[1,2].
At	the	same	time,	S. aureus	showed	a	relatively	smaller	
increase	in	the	number	of	reported	BSIs,	but	a	signifi-
cant	decrease	in	the	proportion	of	MRSA	overall	in	the	
countries	participating	in	EARSS/EARS-Net.	This	could	
be	 the	 result	 of	 public	 health	 efforts	 targeted	 at	 the	
containment	 of	MRSA	 in	 several	 European	 countries.*	
Although	an	overall	decreasing	 trend	 for	MRSA	 is	evi-
dent	 in	 Europe,	 not	 all	 countries	 contribute	 to	 this	
result.	Efforts	to	reduce	the	occurrence	of	MRSA	should	
remain	a	priority	irrespective	of	decreasing	trends.	
In	 this	 context,	 coordinated	 international	 surveillance	
is	 particularly	 important	 in	 order	 to	 obtain	 accurate	
knowledge	of	 the	occurrence	and	spread	of	antimicro-
bial	resistance	and	to	plan	public	health	interventions.
* Authors’ correction:
At	 the	 request	 of	 the	 authors,	 the	 following	 correction	 was	made	
on	 18	March	 2011:	 The	 sentence	 ‘This	 could	 be	 the	 result	 of	 pub-
lic	 health	 efforts	 targeted	 at	 the	 containment	 of	 MRSA	 in	 several	
European	countries	and	in	the	United	States.’	was	changed	to	‘This	
could	be	the	result	of	public	health	efforts	targeted	at	the	contain-
ment	of	MRSA	in	several	European	countries.’
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